<- Go Home

CTI BioPharma Corp.

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington. As of June 26, 2023, CTI BioPharma Corp. operates as a subsidiary of Swedish Orphan Biovitrum AB (publ).

Market Cap

$1.2B

Volume

3.8M

Cash and Equivalents

$24.2M

EBITDA

-$53.6M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

$71.3M

Profit Margin

94.11%

52 Week High

$9.10

52 Week Low

$4.00

Dividend

N/A

Price / Book Value

-47.29

Price / Earnings

-16.10

Price / Tangible Book Value

-24.95

Enterprise Value

$1.3B

Enterprise Value / EBITDA

-23.90

Operating Income

-$55.7M

Return on Equity

259.98%

Return on Assets

-28.58

Cash and Short Term Investments

$59.0M

Debt

$118.3M

Equity

-$25.3M

Revenue

$75.8M

Unlevered FCF

-$74.1M

Sector

Biotechnology

Category

N/A

Hedge Funds that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Yellowbrick Portfolios that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Company Stock Pitches